Suzhou Sheng Diya Biomedical Co., Ltd. Report issue

For profit Phase 2

Organization Overview

First Clinical Trial
2020
NCT04459078
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Suzhou Sheng Diya Biomedical Co., Ltd.

Active Ingredients

Drugs in Phase 2 Trials (3)

camrelizumab (1 trial)

lapatinib (tykerb) (1 trial)

paclitaxel (taxol) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 2)

Adenocarcinoma of Lung (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 3